Cytek Biosciences Inc (CTKB)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 425,546 | 405,385 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $393,064K
= 0.00
The debt-to-equity ratio of Cytek Biosciences Inc has been consistently 0.00 for the past three years, including as of December 31, 2023, December 31, 2022, and December 31, 2021. This indicates that the company has not had any debt on its balance sheet relative to its equity during this period. A debt-to-equity ratio of 0.00 signifies that the company has been entirely reliant on equity financing to fund its operations and growth, with no obligations to external creditors.
While having no debt may suggest a lower financial risk for the company as it does not have interest payments or principal repayments to worry about, it may also mean that Cytek Biosciences Inc is potentially missing out on the tax benefits associated with debt financing. Furthermore, a consistently low or zero debt-to-equity ratio over multiple years may prompt questions about the company's capital structure strategy and its ability to leverage debt effectively to optimize its capital resources. It is important for investors and stakeholders to closely monitor the company's capital structure decisions and financial policies to ensure sustainable and efficient growth.
Peer comparison
Dec 31, 2023